MetaCap

Inventiva S.A. American Depository Shares (IVA)

NASDAQ: IVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.14-0.31 (-8.99%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IVA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$750.78M
EPS (TTM)
-$0.62
52-week range
2.82 – 7.29
Day range
3.13 – 3.44
Volume / Avg
3.02M / 2.40M
Beta
—

52-week range

$2.82$7.29

IVA stock today

On Nov 20, IVA ended the session at $3.14, shedding $0.31 (8.99%), versus the S&P 500's 3.70% decline. At this level, IVA sits near the bottom of its 52-week range of $2.82 to $7.29: 56.9% below the high, set on Jan 26, 2026 and 11.3% above the low. IVA is down 32.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.0%.

Inventiva S.A. American Depository Shares has posted a net loss over the last twelve months (EPS of -$0.62), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Inventiva S.A. American Depository Shares

Company profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Andrew Obenshain
Headquarters
Daix
Employees
87
IPO year
2020

Financial highlights

Full financials

Inventiva S.A. American Depository Shares reported a net loss of $49.6 million.

Inventiva S.A. American Depository Shares annual revenue, net income and EPS
Fiscal yearFY 2021
Revenue—
Growth—
Net income$-49.63M
EPS (diluted)—

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$14.42+359.24%

  • Strong buy 1
  • Buy 12
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $26.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

IVA news

All IVA news

Inventiva S.A. American Depository Shares peers

Health Care sector
IVA peer companies
CompanyPrice% ChgMarket capCompare
ARDXArdelyx Inc.2.99-2.29%$751.60Mvs IVA
RIGLRigel Pharmaceuticals Inc.40.09-2.67%$754.89Mvs IVA
OBXObsidian Therapeutics Inc.12.00-1.23%$741.29Mvs IVA
ORICOric Pharmaceuticals Inc.7.36-4.42%$764.94Mvs IVA
COLLCollegium Pharmaceutical Inc.24.72-1.94%$768.18Mvs IVA
IRWDIronwood Pharmaceuticals Inc. Class A4.70-0.21%$778.09Mvs IVA
SNDXSyndax Pharmaceuticals Inc.8.72-4.49%$785.05Mvs IVA
VSTMVerastem Inc.6.33-7.73%$797.67Mvs IVA

Indexes, lists and sector

Inventiva S.A. American Depository Shares stock FAQ

What is Inventiva S.A. American Depository Shares's stock price today?

IVA last traded at $3.14 as of Nov 20, 4:00 PM EST, down 8.99% on the day. Prices are delayed at least 15 minutes.

Who is Inventiva S.A. American Depository Shares's CEO?

Mr. Andrew Obenshain is the chief executive officer of Inventiva S.A. American Depository Shares, which has about 87 employees.

What is the IVA 52-week high?

The 52-week high for IVA is $7.29 and the 52-week low is $2.82. The stock is currently 56.9% below its high.

Compare IVA